Renal cancer

Gideon Blecher; Benjamin Challacombe

doi:10.1016/j.mpsur.2016.07.003

Renal cancer

Research output: Contribution to journal › Literature review › peer-review

Abstract

Renal carcinoma is a reasonably common cancer in the UK. Fortunately, its diagnosis is nowadays much earlier due to the increased utilization of radiological imaging. Whilst surveillance is an option, particularly in older/comorbid patients, nephron sparing surgery remains the gold standard treatment for small renal masses. Laparoscopic, robotic or open partial nephrectomy have excellent cure rates. For larger tumours, radical nephrectomy may be required. This again can be performed laparoscopically, robotically or in an open manner. The classic presentation of renal mass, haematuria and loin pain is a late presentation – many of these patients will already have metastatic disease. Although non-curable, treatments are available for metastatic disease. Surgical options in the form of cytoreductive nephrectomy and metastasectomy can improve overall survival. Tyrosine kinase inhibitors and other targeted novel agents contribute the non-surgical treatments and have demonstrated increases in survival.

Original language	English
Journal	Surgery
DOIs	https://doi.org/10.1016/j.mpsur.2016.07.003
Publication status	Published - 9 Sept 2016

Keywords

Ablation
cancer
carcinoma
kidney
nephrectomy
nephron sparing
partial
radical
renal

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.mpsur.2016.07.003

Cite this

@article{478a5842407b476a948e54acfa090255,

title = "Renal cancer",

abstract = "Renal carcinoma is a reasonably common cancer in the UK. Fortunately, its diagnosis is nowadays much earlier due to the increased utilization of radiological imaging. Whilst surveillance is an option, particularly in older/comorbid patients, nephron sparing surgery remains the gold standard treatment for small renal masses. Laparoscopic, robotic or open partial nephrectomy have excellent cure rates. For larger tumours, radical nephrectomy may be required. This again can be performed laparoscopically, robotically or in an open manner. The classic presentation of renal mass, haematuria and loin pain is a late presentation – many of these patients will already have metastatic disease. Although non-curable, treatments are available for metastatic disease. Surgical options in the form of cytoreductive nephrectomy and metastasectomy can improve overall survival. Tyrosine kinase inhibitors and other targeted novel agents contribute the non-surgical treatments and have demonstrated increases in survival.",

keywords = "Ablation, cancer, carcinoma, kidney, nephrectomy, nephron sparing, partial, radical, renal",

author = "Gideon Blecher and Benjamin Challacombe",

year = "2016",

month = sep,

day = "9",

doi = "10.1016/j.mpsur.2016.07.003",

language = "English",

journal = "Surgery",

issn = "0263-9319",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Renal cancer

AU - Blecher, Gideon

AU - Challacombe, Benjamin

PY - 2016/9/9

Y1 - 2016/9/9

N2 - Renal carcinoma is a reasonably common cancer in the UK. Fortunately, its diagnosis is nowadays much earlier due to the increased utilization of radiological imaging. Whilst surveillance is an option, particularly in older/comorbid patients, nephron sparing surgery remains the gold standard treatment for small renal masses. Laparoscopic, robotic or open partial nephrectomy have excellent cure rates. For larger tumours, radical nephrectomy may be required. This again can be performed laparoscopically, robotically or in an open manner. The classic presentation of renal mass, haematuria and loin pain is a late presentation – many of these patients will already have metastatic disease. Although non-curable, treatments are available for metastatic disease. Surgical options in the form of cytoreductive nephrectomy and metastasectomy can improve overall survival. Tyrosine kinase inhibitors and other targeted novel agents contribute the non-surgical treatments and have demonstrated increases in survival.

AB - Renal carcinoma is a reasonably common cancer in the UK. Fortunately, its diagnosis is nowadays much earlier due to the increased utilization of radiological imaging. Whilst surveillance is an option, particularly in older/comorbid patients, nephron sparing surgery remains the gold standard treatment for small renal masses. Laparoscopic, robotic or open partial nephrectomy have excellent cure rates. For larger tumours, radical nephrectomy may be required. This again can be performed laparoscopically, robotically or in an open manner. The classic presentation of renal mass, haematuria and loin pain is a late presentation – many of these patients will already have metastatic disease. Although non-curable, treatments are available for metastatic disease. Surgical options in the form of cytoreductive nephrectomy and metastasectomy can improve overall survival. Tyrosine kinase inhibitors and other targeted novel agents contribute the non-surgical treatments and have demonstrated increases in survival.

KW - Ablation

KW - cancer

KW - carcinoma

KW - kidney

KW - nephrectomy

KW - nephron sparing

KW - partial

KW - radical

KW - renal

U2 - 10.1016/j.mpsur.2016.07.003

DO - 10.1016/j.mpsur.2016.07.003

M3 - Literature review

SN - 0263-9319

JO - Surgery

JF - Surgery

ER -

Renal cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this